default author photo

Eiji Iwama

Kyushu University - Kyushu University Hospital

Japan

SCHOLARLY PAPERS

3

DOWNLOADS

92

TOTAL CITATIONS

0

Scholarly Papers (3)

1.

A Phase II, Open Label, Single-Arm Study on the Efficacy of Cabozantinib in Patients with Advanced/Metastatic Nonsmall Cell Lung Cancer Harboring Met Exon 14 Alterations Who Developed Acquired Resistance to Tepotinib or Capmatinib (CAPTURE Trial)

Number of pages: 11 Posted: 29 Aug 2024
Kindai University, Nara Medical University, Kyushu University - Kyushu University Hospital, Sendai Kousei Hospital - Department of Pulmonary Medicine, Juntendo University, affiliation not provided to SSRN, Niigata Cancer Center Hospital, National Hospital Organization Nagoya Medical Center, Kindai University, Hiroshima University - Hiroshima University Hospital, Ehime University and Yamaguchi University
Downloads 40 (1,183,237)

Abstract:

Loading...

Lung cancer, MET, acquired resistance, cabozantinib, clinical trial

2.

Biological Impact of Chemotherapy During Treatment with Egfr Tyrosine Kinase Inhibitors for Non-Small Cell Lung Cancer Positive for Egfr Activating Mutations

Number of pages: 24 Posted: 11 Apr 2025
Kyushu University - Kyushu University Hospital, Kindai University - Kindai University Hospital, affiliation not provided to SSRN, Shinshu University - Department of Hematology and Medical Oncology, Sendai Kousei Hospital - Department of Pulmonary Medicine, Kurashiki Central Hospital - Department of Respiratory Medicine, Nagasaki University, Kindai University, National Hospital Organization Kyushu Cancer Center, Niigata Cancer Center Hospital, National Cancer Center Hospital East, Saitama Cancer Center, Tokushima University, National Hospital Organization Hokkaido Medical Center, Kyushu University - Kyushu University Hospital, Kindai University, Wakayama Medical University - Department of Pulmonary Medicine and Medical Oncology, National Cancer Center Hospital and Kyushu University - Kyushu University Hospital
Downloads 33 (1,277,121)

Abstract:

Loading...

Epidermal growth factor receptor (EGFR), Tyrosine kinase inhibitor, Circulating tumor DNA, chemotherapy, Osimertinib

3.

Tumor size assessment for prediction of osimertinib efficacy in EGFR-mutated non–small cell lung cancer

Number of pages: 20 Posted: 24 Dec 2025
Kyushu University, Kyushu University - Kyushu University Hospital, Kyushu University, Kyushu University, Kyushu University, Kyushu University - Kyushu University Hospital, Kyushu University, affiliation not provided to SSRN and Kyushu University - Kyushu University Hospital
Downloads 19 (1,459,862)

Abstract:

Loading...

Epidermal growth factor receptor (EGFR)Tyrosine kinase inhibitorOsimertinibTumor sizePrimary lesion